» Articles » PMID: 37664239

Ion Channels in Cancer-induced Bone Pain: from Molecular Mechanisms to Clinical Applications

Overview
Specialty Molecular Biology
Date 2023 Sep 4
PMID 37664239
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer-induced bone pain (CIBP) caused by bone metastasis is one of the most prevalent diseases, and current treatments rely primarily on opioids, which have significant side effects. However, recent developments in pharmaceutical science have identified several new mechanisms for CIBP, including the targeted modification of certain ion channels and receptors. Ion channels are transmembrane proteins, which are situated on biological cell membranes, which facilitate passive transport of inorganic ions across membranes. They are involved in various physiological processes, including transmission of pain signals in the nervous system. In recent years, there has been an increasing interest in the role of ion channels in chronic pain, including CIBP. Therefore, in this review, we summarize the current literature on ion channels, related receptors, and drugs and explore the mechanism of CIBP. Targeting ion channels and regulating their activity might be key to treating pain associated with bone cancer and offer new treatment avenues.

Citing Articles

Unveiling the Mechanisms of Pain in Endometriosis: Comprehensive Analysis of Inflammatory Sensitization and Therapeutic Potential.

Chen Y, Li T Int J Mol Sci. 2025; 26(4).

PMID: 40004233 PMC: 11855056. DOI: 10.3390/ijms26041770.


Role of TRP Channels in Cancer-Induced Bone Pain.

Coluzzi F, Scerpa M, Alessandri E, Romualdi P, Rocco M Int J Mol Sci. 2025; 26(3).

PMID: 39940997 PMC: 11818569. DOI: 10.3390/ijms26031229.


Involvement of HDAC2-mediated kcnq2/kcnq3 genes transcription repression activated by EREG/EGFR-ERK-Runx1 signaling in bone cancer pain.

Zhang Z, Tian Y, Li S, Jing H, Cai J, Li M Cell Commun Signal. 2024; 22(1):416.

PMID: 39192337 PMC: 11350972. DOI: 10.1186/s12964-024-01797-2.


Targeting TRPV4 Channels for Cancer Pain Relief.

Antoniazzi C, Andrighetto Ruviaro N, Peres D, Rodrigues P, Viero F, Trevisan G Cancers (Basel). 2024; 16(9).

PMID: 38730655 PMC: 11083562. DOI: 10.3390/cancers16091703.


Targeting TRPV1 for Cancer Pain Relief: Can It Work?.

Szallasi A Cancers (Basel). 2024; 16(3).

PMID: 38339399 PMC: 11154559. DOI: 10.3390/cancers16030648.


References
1.
Rami H, Thompson M, Stemp G, Fell S, Jerman J, Stevens A . Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. Bioorg Med Chem Lett. 2006; 16(12):3287-91. DOI: 10.1016/j.bmcl.2006.03.030. View

2.
Montell C . Physiology, phylogeny, and functions of the TRP superfamily of cation channels. Sci STKE. 2001; 2001(90):re1. DOI: 10.1126/stke.2001.90.re1. View

3.
Moqrich A, Hwang S, Earley T, Petrus M, Murray A, Spencer K . Impaired thermosensation in mice lacking TRPV3, a heat and camphor sensor in the skin. Science. 2005; 307(5714):1468-72. DOI: 10.1126/science.1108609. View

4.
Jin X, Cheng J, Zhang Q, Ji H, Zhu C, Yang Y . Aconitine - A promising candidate for treating cold and mechanical allodynia in cancer induced bone pain. Biomed Pharmacother. 2023; 161:114284. DOI: 10.1016/j.biopha.2023.114284. View

5.
Menendez L, Juarez L, Garcia E, Garcia-Suarez O, Hidalgo A, Baamonde A . Analgesic effects of capsazepine and resiniferatoxin on bone cancer pain in mice. Neurosci Lett. 2005; 393(1):70-3. DOI: 10.1016/j.neulet.2005.09.046. View